Sugi Predict

Sugi Predict / Compounds / SCHEMBL814418

SCHEMBL814418

SCHEMBL814418

OCCCCCCCOCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ UGCG Q16739 5/20 0.50
▸ GBA2 Q9HCG7 5/20 0.50
▸ GBA1 P04062 4/20 0.50
▸ EPHX2 P34913 3/20 0.47
▸ LTA4H P09960 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HRH4 Q9H3N8 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.45
▸ ADRB2 P07550 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ LCT P09848 2/20 0.43
▸ SI P14410 2/20 0.43
▸ MGAM O43451 1/20 0.43
▸ TEAD3 Q99594 1/20 0.42
▸ NAAA Q02083 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL518615 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL1246210 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL8482826 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL6212152 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL96809 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL9684333 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL25208054 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL97795 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL1007794 1.00 L3MBTL1 (0.54) L3MBTL1TDP1TSHRUGCGGBA2
SCHEMBL22906771 0.98 L3MBTL1 (0.53) L3MBTL1TDP1TSHRUGCGGBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-05-14 — — US disclosed
EP-4739652-A1 LIPIDS AND COMPOSITIONS THEREOF Kernal Biologics, Inc. (US) 2026-05-13 — — EP disclosed
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS INC (US) 2026-04-30 — — US disclosed
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof SEAPORT THERAPEUTICS, INC. (US) 2026-04-07 — — US disclosed
US-20250243220-A1 ATR INHIBITORS APREA THERAPEUTICS, INC. 2025-07-31 — — US disclosed
WO-2025134071-A1 MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS SANOFI (FR) 2025-06-26 — — WO disclosed
WO-2025090809-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2025-05-01 — — WO disclosed
EP-4511128-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF Kumquat Biosciences Inc. (US) 2025-02-26 — — EP disclosed
US-20250057747-A1 ORGANIC COMPOUNDS AS FRAGRANCE GIVAUDAN SA (CH) 2025-02-20 — — US disclosed
EP-4507791-A1 ATR INHIBITORS Aprea Therapeutics, Inc. (US) 2025-02-19 — — EP disclosed
US-20090312432-A1 FLUOROSURFACTANTS MERCK PATENT GESELLSCHAFT (DE) 2009-12-17 — — US disclosed
US-20090312432-A1 FLUOROSURFACTANTS MERCK PATENT GESELLSCHAFT (DE) 2009-12-17 — — US disclosed
US-20090264525-A1 FLUOROSURFACTANTS MERCK PATENT GMBH (DE) 2009-10-22 — — US disclosed
US-20090264525-A1 FLUOROSURFACTANTS MERCK PATENT GMBH (DE) 2009-10-22 — — US disclosed
US-20090264525-A1 FLUOROSURFACTANTS MERCK PATENT GMBH (DE) 2009-10-22 — — US disclosed
EP-2035130-A1 FLUOROSURFACTANTS Merck Patent GmbH (DE) 2009-03-18 — — EP disclosed
EP-2035363-A1 FLUOROSURFACANTS Merck Patent GmbH (DE) 2009-03-18 — — EP disclosed
WO-2008003444-A1 FLUOROSURFACANTS MERCK PATENT GMBH (DE) 2008-01-10 — — WO disclosed
WO-2008003444-A1 FLUOROSURFACANTS MERCK PATENT GMBH (DE) 2008-01-10 — — WO disclosed
WO-2008003445-A1 FLUOROSURFACTANTS MERCK PATENT GMBH (DE) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KRAS, HRAS, BCL6 L3MBTL1 574/4885TDP1 2369/4885TSHR 371/4885
US-20090312432-A1 FLUOROSURFACTANTS SGMS2, FASN, SGMS1 L3MBTL1 3955/4885TDP1 4793/4885TSHR 1160/4885
US-20250243220-A1 ATR INHIBITORS ATR, CHEK1, CHEK2 L3MBTL1 847/4885TDP1 22/4885TSHR 2070/4885
US-20250057747-A1 ORGANIC COMPOUNDS AS FRAGRANCE OPRK1, MAFK, OPRM1 L3MBTL1 2979/4885TDP1 4278/4885TSHR 4334/4885
US-20090264525-A1 FLUOROSURFACTANTS FASN, FFAR3, SGMS2 L3MBTL1 4360/4885TDP1 4827/4885TSHR 754/4885
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof JAK1, JAK3, JAK2 L3MBTL1 2032/4885TDP1 1878/4885TSHR 432/4885
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF LIPC, LIPA, NPC1L1 L3MBTL1 295/4885TDP1 1579/4885TSHR 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.